BioCentury | Jun 14, 2017
Financial News

Athenex ticks up after $66M IPO

...tubulin polymerization. The company was formerly known as Kinex Pharmaceuticals LLC . Mary Romeo Cyramza Oraxol topical KX01 Athenex Inc. Eli Lilly and Co. Kinex Pharmaceuticals LLC P...
BioCentury | Feb 8, 2016
Strategy

Worldwide web

...rights to develop and commercialize poziotinib Ph II Undisclosed $20 Yes Aug-14 Athenex Inc. (formerly Kinex Pharmaceuticals LLC...
...an inhibitor of Src tyrosine kinase signaling and tubulin polymerization from Athenex Inc. (formerly Kinex Pharmaceuticals LLC...
BioCentury | Nov 10, 2015
Company News

Hanmi continues partnership spree

...Inc. (NASDASQ:SPPI) and Eli Lilly and Co. (NYSE:LLY), as well as an expanded deal with Kinex Pharmaceuticals LLC...
BioCentury | May 25, 2015
Financial News

Kinex Pharmaceuticals completes venture financing

Kinex Pharmaceuticals LLC , Buffalo, N.Y. Business: Cancer Date completed: 2015-05-20 Type: Venture financing Raised: $48.1 million Investors: Individual investor; Strategic investors Note: Kinex raised $48.1 million of a planned $63.8 million offering, according to an...
BioCentury | Mar 30, 2015
Company News

Hanmi Pharmaceutical Co. Ltd, Kinex Pharmaceuticals deal

...15, 2013 & Nov. 4, 2013). Hanmi Pharmaceutical Co. Ltd . (KOSDAQ:128940), Seoul, South Korea Kinex Pharmaceuticals LLC...
BioCentury | Jan 12, 2015
Clinical News

KX2-361: Phase I started

...and commercialize KX2-361 for cancer in China, Taiwan and Singapore (see BioCentury, May 28, 2012). Kinex Pharmaceuticals LLC...
BioCentury | Jan 5, 2015
Company News

Kinex Pharmaceuticals management update

Kinex Pharmaceuticals LLC , Buffalo, N.Y. Business: Cancer Transitioned: Flint Besecker to COO from EVP, CFO and CBO, while remaining a director WIR Staff cancer...
BioCentury | Apr 10, 2014
Cover Story

Pre-EMP-tive strike against GBM

...CD51/CD29) Phase II for melanoma and castration-resistant prostate cancer (CRPC); Phase I for solid tumors Kinex Pharmaceuticals LLC/Hanmi...
BioCentury | Mar 31, 2014
Clinical News

Oraxol: Phase I start

...and commercialization rights from Kinex to Oraxol in Taiwan and Singapore (see BioCentury, Feb. 17). Kinex Pharmaceuticals LLC...
BioCentury | Mar 10, 2014
Financial News

Kinex Pharmaceuticals completes venture financing

Kinex Pharmaceuticals LLC , Buffalo, N.Y. Business: Cancer Date completed: 3/4/14 Type: Venture financing Raised: $40 million Investors: Institutional investors; existing investors WIR Staff cancer...
Items per page:
1 - 10 of 41
BioCentury | Jun 14, 2017
Financial News

Athenex ticks up after $66M IPO

...tubulin polymerization. The company was formerly known as Kinex Pharmaceuticals LLC . Mary Romeo Cyramza Oraxol topical KX01 Athenex Inc. Eli Lilly and Co. Kinex Pharmaceuticals LLC P...
BioCentury | Feb 8, 2016
Strategy

Worldwide web

...rights to develop and commercialize poziotinib Ph II Undisclosed $20 Yes Aug-14 Athenex Inc. (formerly Kinex Pharmaceuticals LLC...
...an inhibitor of Src tyrosine kinase signaling and tubulin polymerization from Athenex Inc. (formerly Kinex Pharmaceuticals LLC...
BioCentury | Nov 10, 2015
Company News

Hanmi continues partnership spree

...Inc. (NASDASQ:SPPI) and Eli Lilly and Co. (NYSE:LLY), as well as an expanded deal with Kinex Pharmaceuticals LLC...
BioCentury | May 25, 2015
Financial News

Kinex Pharmaceuticals completes venture financing

Kinex Pharmaceuticals LLC , Buffalo, N.Y. Business: Cancer Date completed: 2015-05-20 Type: Venture financing Raised: $48.1 million Investors: Individual investor; Strategic investors Note: Kinex raised $48.1 million of a planned $63.8 million offering, according to an...
BioCentury | Mar 30, 2015
Company News

Hanmi Pharmaceutical Co. Ltd, Kinex Pharmaceuticals deal

...15, 2013 & Nov. 4, 2013). Hanmi Pharmaceutical Co. Ltd . (KOSDAQ:128940), Seoul, South Korea Kinex Pharmaceuticals LLC...
BioCentury | Jan 12, 2015
Clinical News

KX2-361: Phase I started

...and commercialize KX2-361 for cancer in China, Taiwan and Singapore (see BioCentury, May 28, 2012). Kinex Pharmaceuticals LLC...
BioCentury | Jan 5, 2015
Company News

Kinex Pharmaceuticals management update

Kinex Pharmaceuticals LLC , Buffalo, N.Y. Business: Cancer Transitioned: Flint Besecker to COO from EVP, CFO and CBO, while remaining a director WIR Staff cancer...
BioCentury | Apr 10, 2014
Cover Story

Pre-EMP-tive strike against GBM

...CD51/CD29) Phase II for melanoma and castration-resistant prostate cancer (CRPC); Phase I for solid tumors Kinex Pharmaceuticals LLC/Hanmi...
BioCentury | Mar 31, 2014
Clinical News

Oraxol: Phase I start

...and commercialization rights from Kinex to Oraxol in Taiwan and Singapore (see BioCentury, Feb. 17). Kinex Pharmaceuticals LLC...
BioCentury | Mar 10, 2014
Financial News

Kinex Pharmaceuticals completes venture financing

Kinex Pharmaceuticals LLC , Buffalo, N.Y. Business: Cancer Date completed: 3/4/14 Type: Venture financing Raised: $40 million Investors: Institutional investors; existing investors WIR Staff cancer...
Items per page:
1 - 10 of 41